Annual EBITDA
-$139.03 M
-$34.83 M-33.43%
31 December 2023
Summary:
Celldex Therapeutics annual earnings before interest, taxes, depreciation & amortization is currently -$139.03 million, with the most recent change of -$34.83 million (-33.43%) on 31 December 2023. During the last 3 years, it has fallen by -$93.39 million (-204.61%). CLDX annual EBITDA is now -3080.36% below its all-time high of $4.67 million, reached on 31 December 2010.CLDX EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly EBITDA
-$51.34 M
-$5.82 M-12.79%
01 September 2024
Summary:
Celldex Therapeutics quarterly earnings before interest, taxes, depreciation & amortization is currently -$51.34 million, with the most recent change of -$5.82 million (-12.79%) on 01 September 2024. Over the past year, it has dropped by -$10.87 million (-26.85%). CLDX quarterly EBITDA is now -287.11% below its all-time high of $27.44 million, reached on 31 December 2010.CLDX Quarterly EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
TTM EBITDA
-$171.06 M
-$10.87 M-6.78%
01 September 2024
Summary:
Celldex Therapeutics TTM earnings before interest, taxes, depreciation & amortization is currently -$171.06 million, with the most recent change of -$10.87 million (-6.78%) on 01 September 2024. Over the past year, it has dropped by -$39.18 million (-29.71%). CLDX TTM EBITDA is now -3767.69% below its all-time high of $4.66 million, reached on 31 December 2010.CLDX TTM EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
CLDX EBITDA Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | -33.4% | -26.9% | -29.7% |
| 3 y3 years | -204.6% | -177.9% | -206.7% |
| 5 y5 years | -91.5% | -302.7% | -234.1% |
CLDX EBITDA High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3 years | -204.6% | at low | -177.9% | at low | -206.7% | at low |
| 5 y | 5 years | -204.6% | at low | -440.0% | at low | -274.8% | at low |
| alltime | all time | -3080.4% | at low | -287.1% | at low | -3767.7% | at low |
Celldex Therapeutics EBITDA History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2024 | - | -$51.34 M(+12.8%) | -$171.06 M(+6.8%) |
| June 2024 | - | -$45.52 M(+14.3%) | -$160.19 M(+8.9%) |
| Mar 2024 | - | -$39.83 M(+15.9%) | -$147.12 M(+5.8%) |
| Dec 2023 | -$139.03 M(+33.4%) | -$34.37 M(-15.1%) | -$139.03 M(+5.4%) |
| Sept 2023 | - | -$40.47 M(+24.7%) | -$131.88 M(+11.4%) |
| June 2023 | - | -$32.45 M(+2.2%) | -$118.43 M(+4.8%) |
| Mar 2023 | - | -$31.75 M(+16.7%) | -$112.96 M(+8.4%) |
| Dec 2022 | -$104.20 M(+57.7%) | -$27.21 M(+0.7%) | -$104.20 M(+7.6%) |
| Sept 2022 | - | -$27.02 M(+0.2%) | -$96.80 M(+9.7%) |
| June 2022 | - | -$26.98 M(+17.4%) | -$88.24 M(+19.8%) |
| Mar 2022 | - | -$22.98 M(+16.0%) | -$73.68 M(+11.5%) |
| Dec 2021 | -$66.08 M(+44.8%) | -$19.81 M(+7.2%) | -$66.08 M(+18.5%) |
| Sept 2021 | - | -$18.47 M(+48.8%) | -$55.78 M(+11.3%) |
| June 2021 | - | -$12.42 M(-19.3%) | -$50.13 M(+1.1%) |
| Mar 2021 | - | -$15.38 M(+61.8%) | -$49.56 M(+8.6%) |
| Dec 2020 | -$45.64 M(-8.1%) | -$9.51 M(-25.8%) | -$45.64 M(-4.2%) |
| Sept 2020 | - | -$12.82 M(+8.2%) | -$47.66 M(+0.1%) |
| June 2020 | - | -$11.85 M(+3.3%) | -$47.59 M(-0.6%) |
| Mar 2020 | - | -$11.47 M(-0.5%) | -$47.87 M(-3.6%) |
| Dec 2019 | -$49.67 M(-31.6%) | -$11.53 M(-9.6%) | -$49.67 M(-3.0%) |
| Sept 2019 | - | -$12.75 M(+5.2%) | -$51.20 M(-2.1%) |
| June 2019 | - | -$12.12 M(-8.7%) | -$52.31 M(-17.6%) |
| Mar 2019 | - | -$13.27 M(+1.6%) | -$63.50 M(-12.5%) |
| Dec 2018 | -$72.60 M(-30.2%) | -$13.05 M(-5.8%) | -$72.60 M(-14.0%) |
| Sept 2018 | - | -$13.86 M(-40.5%) | -$84.43 M(-9.1%) |
| June 2018 | - | -$23.31 M(+4.2%) | -$92.88 M(-3.5%) |
| Mar 2018 | - | -$22.37 M(-10.1%) | -$96.27 M(-7.5%) |
| Dec 2017 | -$104.02 M(-19.3%) | -$24.88 M(+11.5%) | -$104.02 M(-7.8%) |
| Sept 2017 | - | -$22.31 M(-16.4%) | -$112.79 M(-5.6%) |
| June 2017 | - | -$26.70 M(-11.4%) | -$119.52 M(-3.8%) |
| Mar 2017 | - | -$30.12 M(-10.5%) | -$124.24 M(-3.6%) |
| Dec 2016 | -$128.82 M(+2.6%) | -$33.66 M(+15.9%) | -$128.82 M(+1.0%) |
| Sept 2016 | - | -$29.04 M(-7.6%) | -$127.51 M(-1.8%) |
| June 2016 | - | -$31.42 M(-9.5%) | -$129.82 M(-0.3%) |
| Mar 2016 | - | -$34.71 M(+7.3%) | -$130.18 M(+3.7%) |
| Dec 2015 | -$125.53 M(+5.5%) | -$32.34 M(+3.1%) | -$125.53 M(+0.9%) |
| Sept 2015 | - | -$31.35 M(-1.4%) | -$124.36 M(+1.5%) |
| June 2015 | - | -$31.78 M(+5.7%) | -$122.50 M(+3.4%) |
| Mar 2015 | - | -$30.06 M(-3.6%) | -$118.43 M(-0.5%) |
| Dec 2014 | -$119.03 M(+53.2%) | -$31.17 M(+5.7%) | -$119.03 M(+9.1%) |
| Sept 2014 | - | -$29.49 M(+6.4%) | -$109.07 M(+7.0%) |
| June 2014 | - | -$27.71 M(-9.6%) | -$101.98 M(+10.8%) |
| Mar 2014 | - | -$30.66 M(+44.5%) | -$92.03 M(+18.5%) |
| Dec 2013 | -$77.68 M(+42.8%) | -$21.21 M(-5.3%) | -$77.68 M(+7.6%) |
| Sept 2013 | - | -$22.39 M(+26.0%) | -$72.19 M(+13.4%) |
| June 2013 | - | -$17.77 M(+9.0%) | -$63.69 M(+8.9%) |
| Mar 2013 | - | -$16.30 M(+3.6%) | -$58.46 M(+7.4%) |
| Dec 2012 | -$54.41 M(+40.1%) | -$15.73 M(+13.3%) | -$54.41 M(+8.5%) |
| Sept 2012 | - | -$13.89 M(+10.8%) | -$50.13 M(+8.2%) |
| June 2012 | - | -$12.54 M(+2.4%) | -$46.35 M(+8.7%) |
| Mar 2012 | - | -$12.25 M(+7.0%) | -$42.64 M(+9.3%) |
| Dec 2011 | -$38.84 M(-932.6%) | -$11.45 M(+13.2%) | -$39.01 M(>+9900.0%) |
| Sept 2011 | - | -$10.11 M(+14.5%) | -$117.00 K(-105.5%) |
| June 2011 | - | -$8.83 M(+2.5%) | $2.13 M(-29.8%) |
| Mar 2011 | - | -$8.61 M(-131.4%) | $3.03 M(-35.0%) |
| Dec 2010 | $4.67 M(-114.1%) | $27.44 M(-448.8%) | $4.66 M(-113.6%) |
| Sept 2010 | - | -$7.87 M(-0.8%) | -$34.42 M(+4.3%) |
| June 2010 | - | -$7.93 M(+13.6%) | -$32.99 M(-0.1%) |
| Mar 2010 | - | -$6.98 M(-40.1%) | -$33.04 M(-0.1%) |
| Dec 2009 | -$33.07 M(-26.2%) | -$11.65 M(+80.8%) | -$33.07 M(-21.1%) |
| Sept 2009 | - | -$6.44 M(-19.2%) | -$41.90 M(-3.1%) |
| June 2009 | - | -$7.98 M(+13.9%) | -$43.22 M(-3.5%) |
| Mar 2009 | - | -$7.00 M(-65.8%) | -$44.79 M(-0.0%) |
| Dec 2008 | -$44.81 M(+205.2%) | -$20.48 M(+163.7%) | -$44.81 M(+57.6%) |
| Sept 2008 | - | -$7.76 M(-18.7%) | -$28.42 M(+14.6%) |
| June 2008 | - | -$9.55 M(+36.0%) | -$24.81 M(+45.3%) |
| Mar 2008 | - | -$7.02 M(+71.5%) | -$17.07 M(+21.5%) |
| Dec 2007 | -$14.68 M(-18.0%) | -$4.09 M(-1.3%) | -$14.05 M(+0.2%) |
| Sept 2007 | - | -$4.15 M(+128.8%) | -$14.02 M(-9.4%) |
| June 2007 | - | -$1.81 M(-54.6%) | -$15.47 M(-20.6%) |
| Mar 2007 | - | -$3.99 M(-1.8%) | -$19.50 M(+8.9%) |
| Dec 2006 | -$17.91 M(+7.0%) | -$4.07 M(-27.4%) | -$17.91 M(+2.4%) |
| Sept 2006 | - | -$5.60 M(-4.0%) | -$17.50 M(+9.5%) |
| June 2006 | - | -$5.83 M(+142.4%) | -$15.98 M(+10.5%) |
| Mar 2006 | - | -$2.41 M(-34.1%) | -$14.46 M(-13.6%) |
| Dec 2005 | -$16.74 M(+41.0%) | -$3.65 M(-10.6%) | -$16.74 M(+1.9%) |
| Sept 2005 | - | -$4.09 M(-5.3%) | -$16.43 M(+4.4%) |
| June 2005 | - | -$4.32 M(-7.7%) | -$15.74 M(+4.9%) |
| Mar 2005 | - | -$4.68 M(+39.9%) | -$15.00 M(+26.4%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Dec 2004 | -$11.87 M(+16.3%) | -$3.34 M(-1.7%) | -$11.87 M(+6.3%) |
| Sept 2004 | - | -$3.40 M(-5.0%) | -$11.16 M(+17.8%) |
| June 2004 | - | -$3.58 M(+132.1%) | -$9.48 M(+9.7%) |
| Mar 2004 | - | -$1.54 M(-41.6%) | -$8.64 M(-14.9%) |
| Dec 2003 | -$10.21 M(-20.3%) | -$2.64 M(+53.6%) | -$10.15 M(-5.2%) |
| Sept 2003 | - | -$1.72 M(-37.3%) | -$10.70 M(+19.1%) |
| June 2003 | - | -$2.74 M(-10.1%) | -$8.99 M(-19.6%) |
| Mar 2003 | - | -$3.05 M(-4.6%) | -$11.17 M(-12.8%) |
| Dec 2002 | -$12.81 M(-42.6%) | -$3.20 M(>+9900.0%) | -$12.81 M(-20.6%) |
| Sept 2002 | - | -$600.00(-100.0%) | -$16.14 M(-27.2%) |
| June 2002 | - | -$4.93 M(+5.1%) | -$22.18 M(-2.9%) |
| Mar 2002 | - | -$4.69 M(-28.2%) | -$22.84 M(+4.1%) |
| Dec 2001 | -$22.30 M(+57.8%) | -$6.53 M(+8.1%) | -$21.95 M(+8.4%) |
| Sept 2001 | - | -$6.04 M(+8.1%) | -$20.26 M(+11.0%) |
| June 2001 | - | -$5.59 M(+47.1%) | -$18.25 M(+18.9%) |
| Mar 2001 | - | -$3.80 M(-21.4%) | -$15.35 M(+8.6%) |
| Dec 2000 | -$14.13 M(+41.9%) | -$4.83 M(+20.0%) | -$14.13 M(+9.1%) |
| Sept 2000 | - | -$4.03 M(+49.8%) | -$12.95 M(+17.5%) |
| June 2000 | - | -$2.69 M(+4.2%) | -$11.03 M(+7.2%) |
| Mar 2000 | - | -$2.58 M(-29.4%) | -$10.29 M(+1.8%) |
| Dec 1999 | -$9.96 M(+43.3%) | -$3.66 M(+74.1%) | -$10.11 M(+20.3%) |
| Sept 1999 | - | -$2.10 M(+7.6%) | -$8.40 M(0.0%) |
| June 1999 | - | -$1.95 M(-18.7%) | -$8.40 M(+5.7%) |
| Mar 1999 | - | -$2.40 M(+23.1%) | -$7.95 M(+14.4%) |
| Dec 1998 | -$6.95 M(-4.9%) | -$1.95 M(-7.2%) | -$6.95 M(+5.2%) |
| Sept 1998 | - | -$2.10 M(+40.0%) | -$6.61 M(+1.5%) |
| June 1998 | - | -$1.50 M(+7.1%) | -$6.51 M(-4.4%) |
| Mar 1998 | - | -$1.40 M(-12.9%) | -$6.81 M(-6.8%) |
| Dec 1997 | -$7.31 M(-35.3%) | -$1.61 M(-19.6%) | -$7.31 M(-12.0%) |
| Sept 1997 | - | -$2.00 M(+11.1%) | -$8.30 M(-1.2%) |
| June 1997 | - | -$1.80 M(-5.3%) | -$8.40 M(-22.9%) |
| Mar 1997 | - | -$1.90 M(-26.9%) | -$10.90 M(-1.8%) |
| Dec 1996 | -$11.30 M(+1.8%) | -$2.60 M(+23.8%) | -$11.10 M(-2.6%) |
| Sept 1996 | - | -$2.10 M(-51.2%) | -$11.40 M(-8.8%) |
| June 1996 | - | -$4.30 M(+104.8%) | -$12.50 M(+16.8%) |
| Mar 1996 | - | -$2.10 M(-27.6%) | -$10.70 M(-3.6%) |
| Dec 1995 | -$11.10 M(+27.6%) | -$2.90 M(-9.4%) | -$11.10 M(+8.8%) |
| Sept 1995 | - | -$3.20 M(+28.0%) | -$10.20 M(+9.7%) |
| June 1995 | - | -$2.50 M(0.0%) | -$9.30 M(+1.1%) |
| Mar 1995 | - | -$2.50 M(+25.0%) | -$9.20 M(+4.5%) |
| Dec 1994 | -$8.70 M(+2.4%) | -$2.00 M(-13.0%) | -$8.80 M(-1.1%) |
| Sept 1994 | - | -$2.30 M(-4.2%) | -$8.90 M(-1.1%) |
| June 1994 | - | -$2.40 M(+14.3%) | -$9.00 M(+7.1%) |
| Mar 1994 | - | -$2.10 M(0.0%) | -$8.40 M(+1.2%) |
| Dec 1993 | -$8.50 M(+107.3%) | -$2.10 M(-12.5%) | -$8.30 M(+33.9%) |
| Sept 1993 | - | -$2.40 M(+33.3%) | -$6.20 M(+26.5%) |
| June 1993 | - | -$1.80 M(-10.0%) | -$4.90 M(+8.9%) |
| Mar 1993 | - | -$2.00 M(+81.8%) | -$4.50 M(-8.2%) |
| Dec 1992 | -$4.10 M(-30.5%) | - | - |
| Oct 1992 | - | -$1.10 M(-21.4%) | -$4.90 M(-14.0%) |
| July 1992 | - | -$1.40 M(-17.6%) | -$5.70 M(-3.4%) |
| Apr 1992 | - | -$1.70 M(+142.9%) | -$5.90 M(+11.3%) |
| Apr 1992 | -$5.90 M(+55.3%) | - | - |
| Jan 1992 | - | -$700.00 K(-63.2%) | -$5.30 M(-3.6%) |
| Oct 1991 | - | -$1.90 M(+18.8%) | -$5.50 M(+25.0%) |
| July 1991 | - | -$1.60 M(+45.5%) | -$4.40 M(+12.8%) |
| Apr 1991 | -$3.80 M(+171.4%) | -$1.10 M(+22.2%) | -$3.90 M(+50.0%) |
| Jan 1991 | - | -$900.00 K(+12.5%) | -$2.60 M(+44.4%) |
| Oct 1990 | - | -$800.00 K(-27.3%) | -$1.80 M(-228.6%) |
| July 1990 | - | -$1.10 M(-650.0%) | $1.40 M(-69.6%) |
| Apr 1990 | -$1.40 M(+7.7%) | $200.00 K(-300.0%) | $4.60 M(-270.4%) |
| Jan 1990 | - | -$100.00 K(-104.2%) | -$2.70 M(+285.7%) |
| Oct 1989 | - | $2.40 M(+14.3%) | -$700.00 K(-41.7%) |
| July 1989 | - | $2.10 M(-129.6%) | -$1.20 M(-25.0%) |
| Apr 1989 | -$1.30 M(-27.8%) | -$7.10 M(-473.7%) | -$1.60 M(+433.3%) |
| Jan 1989 | - | $1.90 M(0.0%) | -$300.00 K(-57.1%) |
| Oct 1988 | - | $1.90 M(+11.8%) | -$700.00 K(-50.0%) |
| July 1988 | - | $1.70 M(-129.3%) | -$1.40 M(-33.3%) |
| Apr 1988 | -$1.80 M(+28.6%) | -$5.80 M(-486.7%) | -$2.10 M(-2200.0%) |
| Jan 1988 | - | $1.50 M(+25.0%) | $100.00 K(-116.7%) |
| Oct 1987 | - | $1.20 M(+20.0%) | -$600.00 K(-50.0%) |
| July 1987 | - | $1.00 M(-127.8%) | -$1.20 M(-40.0%) |
| Apr 1987 | -$1.40 M(-22.2%) | -$3.60 M(-550.0%) | -$2.00 M(+400.0%) |
| Jan 1987 | - | $800.00 K(+33.3%) | -$400.00 K(-63.6%) |
| Oct 1986 | - | $600.00 K(+200.0%) | -$1.10 M(-31.3%) |
| July 1986 | - | $200.00 K(-110.0%) | -$1.60 M(-5.9%) |
| Apr 1986 | -$1.80 M | -$2.00 M(-2100.0%) | -$1.70 M(-666.7%) |
| Jan 1986 | - | $100.00 K(0.0%) | $300.00 K(+50.0%) |
| Oct 1985 | - | $100.00 K(0.0%) | $200.00 K(+100.0%) |
| July 1985 | - | $100.00 K | $100.00 K |
FAQ
- What is Celldex Therapeutics annual earnings before interest, taxes, depreciation & amortization?
- What is the all time high annual EBITDA for Celldex Therapeutics?
- What is Celldex Therapeutics annual EBITDA year-on-year change?
- What is Celldex Therapeutics quarterly earnings before interest, taxes, depreciation & amortization?
- What is the all time high quarterly EBITDA for Celldex Therapeutics?
- What is Celldex Therapeutics quarterly EBITDA year-on-year change?
- What is Celldex Therapeutics TTM earnings before interest, taxes, depreciation & amortization?
- What is the all time high TTM EBITDA for Celldex Therapeutics?
- What is Celldex Therapeutics TTM EBITDA year-on-year change?
What is Celldex Therapeutics annual earnings before interest, taxes, depreciation & amortization?
The current annual EBITDA of CLDX is -$139.03 M
What is the all time high annual EBITDA for Celldex Therapeutics?
Celldex Therapeutics all-time high annual earnings before interest, taxes, depreciation & amortization is $4.67 M
What is Celldex Therapeutics annual EBITDA year-on-year change?
Over the past year, CLDX annual earnings before interest, taxes, depreciation & amortization has changed by -$34.83 M (-33.43%)
What is Celldex Therapeutics quarterly earnings before interest, taxes, depreciation & amortization?
The current quarterly EBITDA of CLDX is -$51.34 M
What is the all time high quarterly EBITDA for Celldex Therapeutics?
Celldex Therapeutics all-time high quarterly earnings before interest, taxes, depreciation & amortization is $27.44 M
What is Celldex Therapeutics quarterly EBITDA year-on-year change?
Over the past year, CLDX quarterly earnings before interest, taxes, depreciation & amortization has changed by -$10.87 M (-26.85%)
What is Celldex Therapeutics TTM earnings before interest, taxes, depreciation & amortization?
The current TTM EBITDA of CLDX is -$171.06 M
What is the all time high TTM EBITDA for Celldex Therapeutics?
Celldex Therapeutics all-time high TTM earnings before interest, taxes, depreciation & amortization is $4.66 M
What is Celldex Therapeutics TTM EBITDA year-on-year change?
Over the past year, CLDX TTM earnings before interest, taxes, depreciation & amortization has changed by -$39.18 M (-29.71%)